Jefferies Financial Group restated their buy rating on shares of PureTech Health (LON:PRTC) in a research note published on Wednesday morning, Digital Look reports. They currently have a GBX 255 ($3.33) target price on the stock.

Several other equities analysts have also recently commented on the stock. Liberum Capital restated a buy rating on shares of PureTech Health in a report on Monday, April 15th. Peel Hunt restated a buy rating on shares of PureTech Health in a report on Tuesday, April 2nd.

LON PRTC opened at GBX 185 ($2.42) on Wednesday. PureTech Health has a twelve month low of GBX 135 ($1.76) and a twelve month high of GBX 188.50 ($2.46). The company has a debt-to-equity ratio of 5.73, a quick ratio of 0.94 and a current ratio of 0.97. The company has a market cap of $522.61 million and a price-to-earnings ratio of 7.17.

PureTech Health Company Profile

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Featured Article: Leveraged Buyout (LBO)

Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.